Martínez-Montoro, José IgnacioPinzón-Martín, José LuisDamas-Fuentes, MiguelFernández-Valero, AndreaTinahones, Francisco J2024-02-272024-02-272022-04-141664-2392http://hdl.handle.net/10668/20559http://hdl.handle.net/20.500.12105/18615Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.engVoRhttp://creativecommons.org/licenses/by/4.0/Type A insulin resistance syndromediabetesglucagon-like peptide-1 receptor agonistinsulin resistancesodium-glucose cotransporter 2 inhibitorBenzhydryl CompoundsDiabetes MellitusGlucagon-Like PeptidesGlucosidesHumansInsulinInsulin ResistanceAttribution 4.0 International354984071383888710.3389/fendo.2022.838887Frontiers in endocrinologyopen access